BSXHealthcare · Medical DevicesThe 31 Wall Street analysts covering Boston Scientific Corp. hold a median 12-month price target of $49 — +6.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 4 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Boston Scientific Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (94): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (6): The shares have been drifting down relative to others.
Size (4): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on BSX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +6.9% from it.
Of the 20 most recent actions, 1 moved their price target up and 15 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Oct 2026 | Barclays | Maintains | Equal-Weight | $48 → $45 |
| 30 Oct 2026 | TD Cowen | Downgrade | Hold | $56 → $46 |
| 29 Oct 2026 | Baird | Maintains | Outperform | $50 → $51 |
| 29 Oct 2026 | Bernstein | Maintains | Outperform | $54 → $49 |
| 29 Oct 2026 | BTIG | Maintains | Buy | $56 → $49 |
| 29 Oct 2026 | Canaccord Genuity | Maintains | Buy | $66 → $48 |
| 29 Oct 2026 | Citigroup | Maintains | Neutral | $48 → $44 |
| 29 Oct 2026 | Jefferies | Downgrade | Hold | $60 → $46 |
| 29 Oct 2026 | Leerink Partners | Maintains | Outperform | $55 → $50 |
| 29 Oct 2026 | RBC Capital | Maintains | Outperform | $70 → $52 |
| 29 Oct 2026 | UBS | Maintains | Buy | $67 → $57 |
| 29 Oct 2026 | Wells Fargo | Maintains | Equal-Weight | $48 → $45 |
| 28 Oct 2026 | Needham | Maintains | Buy | $57 → $48 |
| 26 Oct 2026 | Stifel | Maintains | Buy | $60 → $55 |
| 14 Oct 2026 | Truist Securities | Maintains | Buy | — |
| 14 Oct 2026 | Truist Securities | Maintains | Buy | $57 → $51 |
| 7 Oct 2026 | Barclays | Initiates | Equal-Weight | — |
| 7 Oct 2026 | Barclays | Initiates | Equal-Weight | $48 |
| 5 Oct 2026 | Citigroup | Maintains | Neutral | $50 → $48 |
| 5 Oct 2026 | Citigroup | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BSX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Boston Scientific Corp. returned −53.6% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 39% of US stocks
Cheaper than 38% of US stocks
Cheaper than 34% of US stocks
Cheaper than 25% of US stocks
Higher than 31% of US stocks
Higher than 20% of US stocks
Higher than 83% of US stocks
Higher than 78% of US stocks
Higher than 79% of US stocks
Higher than 73% of US stocks
Higher than 81% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Boston Scientific Corp. has a market value of $66.4B and an enterprise value of $78.0B.
Revenue in the twelve months to 30 June 2026: $21.0B. The latest quarter grew 1.4% year on year.
Net income over the same four quarters: $3.7B, a 17.5% net margin.
Diluted earnings per share, trailing twelve months: $2.47.
Free cash flow in the twelve months to 30 June 2026: $1.8B.
Trailing P/E: 19.3×; forward P/E: 14.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Boston Scientific Corp. employs 59,000 people — $356K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Boston Scientific Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
A cyber disruption cut Boston Scientific's Q3 growth and earnings, prompting lower 2026 guidance. Management described 2027 as the cycle's trough.
Why it matters — The disruption and weaker outlook reset expectations for the company's near-term growth and earnings trajectory.
Zacks Investment Research says Boston Scientific’s valuation discount faces a test amid weakening earnings estimates, slowing momentum in core franchises, and growth catalysts that have shifted to 2028.
Why it matters — BSX watchers may weigh the valuation discount against softer earnings estimates and delayed growth catalysts.
Blackstone Life Sciences announced a $455 million collaboration with Boston Scientific to co-fund development of the VITALYST temporary percutaneous heart pump program. The next-generation system is intended to increase cardiac output and improve blood flow to vital organs.
Why it matters — The collaboration supports development of a Boston Scientific device program intended for patients with cardiogenic shock.
Boston Scientific reported that both post-implant monotherapy regimens in the SIMPLAAFY trial met non-inferiority versus dual antiplatelet therapy at the six-month primary endpoints for the WATCHMAN FLX Pro device.
Why it matters — The results support the potential to simplify post-procedure drug regimens for patients receiving Boston Scientific’s left atrial appendage closure device.
Zacks says Intuitive Surgical’s surging robotic surgery demand and stronger earnings momentum make it a better buy than Boston Scientific, despite Intuitive Surgical’s valuation premium.
Why it matters — The comparison is unfavorable to BSX, as the item presents Intuitive Surgical as the stronger investment choice.
The 31 Wall Street analysts covering Boston Scientific Corp. have a median 12-month price target of $49, with estimates ranging from $41 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 31 analysts covering Boston Scientific Corp., 20 rate it a Buy, 11 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Boston Scientific Corp. 57 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Boston Scientific Corp. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (94 of 100).
No one can know that. What the data says: the median 12-month target from 31 analysts implies +6.9% from the last close, and Ticker Nerd's factor model ranks Boston Scientific Corp. 57 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Boston Scientific Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BSX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $41 to $60 over the next 12 months.
Boston Scientific Corp. returned -53.6% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Boston Scientific Corp. is a medical device company focused on developing, manufacturing, and marketing technologies used in interventional medical procedures worldwide.
The most recent item we track (Zacks Investment Research, 4 Nov 2026): "BSX Q3 Results Reset Growth Expectations as 2027 Outlook Stays Weak". A cyber disruption cut Boston Scientific's Q3 growth and earnings, prompting lower 2026 guidance. Management described 2027 as the cycle's trough.
Boston Scientific Corp. is a medical device company focused on developing, manufacturing, and marketing technologies used in interventional medical procedures worldwide. The company’s portfolio serves a broad range of clinical areas, including cardiology, peripheral interventions, endoscopy, urology, and neuromodulation. Its MedSurg segment covers products for digestive health, urinary care, and pain management, while its Cardiovascular segment supports minimally invasive treatment options for heart and vascular conditions. Boston Scientific’s devices are designed to help healthcare professionals diagnose and treat patients through less invasive approaches across hospitals, clinics, and specialized medical centers. Headquartered in Marlborough, Massachusetts, Boston Scientific plays a significant role in the global health care equipment market through its broad mix of procedure-based products and physician-focused solutions.
CEO Mr. Michael F. Mahoney · 59,000 employees · United States · https://www.bostonscientific.com
